Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 64-70

  Markova, Jana ^a   Kahraman, Deniz ^b   Kobe, Carsten ^b   Skopalova, Magdalena ^c   Mocikova, Heidi ^a   Klaskova, Katerina ^a   Dedeckova, Katerina ^d   Eich, Hans Theodor ^b   Böll, Boris ^b   Dietlein, Markus ^b   Kozak, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

BEACOPP; Chemotherapy; Hodgkin lymphoma; PET; Response assessment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MULTIPLE CYCLE TREATMENT; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROCARBAZINE; PROGNOSIS; RADIOPHARMACEUTICALS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84855460571     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.603444     Document Type: Article

References (25)

1. Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin ' s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27: 4548-4554.
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increaseddose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin ' s disease. N Engl J Med 2003;348:2386-2395. (Pubitemid 36682817)
3. A leman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Longterm cause-specifi c mortality of patients treated for Hodgkin ' s disease. J Clin Oncol 2003;21:3431-3439. (Pubitemid 46603515)
4. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin ' s lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749-1760.
5. Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin ' s disease: a report from the German Hodgkin ' s Lymphoma Study Group. J Clin Oncol 2003;21:3440-3446. (Pubitemid 46594076)
6. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-59. (Pubitemid 43053523)
7. H utchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-1168.
8. G allamini A, Rigacci L, Merli F, et al. Th e predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin ' s disease. Haematologica 2006;91:475-481.
9. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fl uoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advancedstage Hodgkin ' s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
10. G allamini A, Patti C, Viviani S, et al. Early chemotherapy intensifi cation with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551-560.
11. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an eff ective regimen for advanced high-risk Hodgkin ' s lymphoma. Ann Oncol 2010;21:126-132.
12. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905-909. (Pubitemid 46220633)
13. Engert A, Eichenauer DA, Dreyling M. Hodgkin 's lymphoma: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2009;20(Suppl. 4):108-109.
14. Cheson BD, Pfi stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
15. M ocikova H, Obrtlikova P, Vackova B, et al. Positron emission tomography at the end of fi rst-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010;21:1222-1227.
16. M arkova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin ' s lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270-1274.
17. S ieber M, Bredenfeld H, Josting A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin ' s lymphoma: results of a pilot study of the German Hodgkin ' s Lymphoma Study Group. J Clin Oncol 2003;21:1734-1739. (Pubitemid 46638585)
18. J uweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-578. (Pubitemid 350002965)
19. G allamini A, Hutchings M, Avigdor A, et al. Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma 2008;49:659-662. (Pubitemid 351517210)
20. Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:2171-2180.
21. Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging 2010;37:1821-1823.
22. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824-1833.
23. G allamini A, O' D oherty M. Report of satellite workshop on interim- PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma 2011;52:583-586.
24. Furth C, Amthauer H, Hautzel H, et al. Evaluation of interim PET response criteria in paediatric Hodgkin ' s lymphoma-results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 2011;22:1198-1203.
25. L e Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin ' s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38:1064-1071.